K+S AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.82 EUR | +0.14% |
|
+2.22% | -3.46% |
| May. 02 | K+S : Warburg Research gives a Neutral rating | ZD |
| Apr. 30 | K+S : UBS remains a Sell rating | ZD |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.68 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.15 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Agricultural Chemicals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.46% | 2.67B | B | ||
| +19.30% | 39.89B | C | ||
| -.--% | 11.22B | - | B+ | |
| -1.90% | 7.72B | A | ||
| +2.38% | 6.54B | B- | ||
| -5.50% | 5.97B | B+ | ||
| -4.27% | 5.7B | B | ||
| -11.80% | 5.52B | - | C- | |
| +29.81% | 5.13B | B- | ||
| +10.65% | 4B | B- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- SDF Stock
- Ratings K+S AG
